Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza A Virus, H7N9 Subtype
Interventions: H7N9 pLAIV, H7N9 pIIV, AS03 adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 20 Years to 49 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: SARS-CoV-2, Influenza
Interventions: mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 8,061 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 146
States / cities: Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 122 more

Conditions: ARDS, Human, Covid19
Interventions: Longeveron Mesenchymal Stem Cells (LMSCs), Placebo; Biological · Other
Lead sponsor: Longeveron Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Miami, Florida • Baltimore, Maryland • Winston-Salem, North Carolina

Conditions: Asthma, Chronic Obstructive Pulmonary Disease
Interventions: Postcard and IVR Reminder Group, Postcard Only Reminder Group, IVR Only Reminder Group; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 19 Years to 64 Years
Enrollment: 12,255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Influenza-Like Illness, Influenza
Interventions: Core Lab Test, ED Point of Care Test; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza
Interventions: Influenza vaccine; Biological
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Influenza Viral Infections
Interventions: Influenza A/Texas/71/2017 (H3N2), Sham placebo; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 46 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: FluMist; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 3
States / cities: Daytona Beach, Florida • Portland, Oregon • San Antonio, Texas

Conditions: Influenza Prevention, Pandemic Influenza Prevention
Interventions: VRC-FLUMOS0122-00-VP, ALFQ; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: HAI-05 Influenza Vaccine, Saline; Biological · Other
Lead sponsor: Fraunhofer, Center for Molecular Biotechnology; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Wichita, Kansas • Kansas City, Missouri

Conditions: Influenza
Interventions: AS03, Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 789 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Stanford, California • Decatur, Georgia • Iowa City, Iowa + 3 more

Conditions: Influenza A Virus, H7N9 Subtype
Interventions: H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza, Healthy
Interventions: FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018); Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 24 Months to 47 Months
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 12
States / cities: Savannah, Georgia • Bardstown, Kentucky • St Louis, Missouri + 9 more

Conditions: Influenza, Human
Interventions: Oseltamivir, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 44
States / cities: Chandler, Arizona • Costa Mesa, California • Garden Grove, California + 37 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine (2006-2007 Fluzone® vaccine); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Asthma in Children, Vaccine Adverse Reaction, Vaccine Reaction, Asthma, Wheezing, Influenza
Interventions: Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine (IIV); Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 5 Years to 11 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Durham, North Carolina • Cincinnati, Ohio • Nashville, Tennessee

Conditions: Influenza
Interventions: Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 2 Years to 9 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Rochester, New York

Conditions: Influenza
Interventions: Influenza A/H5N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 452 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Torrance, California • Baltimore, Maryland • Rochester, New York

Conditions: Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions: FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®; Biological
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Certolizumab pegol; Other · Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Stanford, California • Torrance, California • Baltimore, Maryland + 2 more

Conditions: Influenza, Human, Vaccine Hesitancy
Interventions: Flu vaccination guide, Accident safety guide; Behavioral
Lead sponsor: Calypta Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Influenza
Interventions: Trivalent influenza vaccine (TIVc), Trivalent influenza vaccine-licensed; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 6 Months to 48 Months
Enrollment: 671 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more

Conditions: Influenza
Interventions: Pumarix™, Pandemrix ™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 780 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more

Search by objective public record fields.

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

Effectiveness of Influenza Vaccine Reminder Systems

Impact of Rapid Flu Testing in BMC ED

Optimizing Influenza Vaccination in Surgical Oncology Patients

Single Dose Texas 2017 (H3N2) Challenge Study

Study To Evaluate the Safety of Bivalent Vaccine

Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults

Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

Safety of LAIV4 in Children With Asthma

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

A/H5N1in Adult - Aventis

Simultaneous RZV and aIIV4 Vaccination

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

Conversational AI for Adult Flu Vaccination Decisions

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults